This FOA invites applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and basic research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.

Highly integrated and synergistic research programs are encouraged for the AADCRC program. This includes multi-institutional applications for diseases of interest to this FOA, especially where research resources are limited (e.g. non-allergic rhinitis or drug allergy). Research programs could be organized around either:

- immunologic mechanisms/pathways that are hypothesized to be an important pathobiologic process in a condition of interest to this FOA, or
- one or more clinical trials or clinical studies that test a novel therapeutic approach, mechanistic hypothesis or aim at elucidating disease phenotypes and endotypes in a condition of interest to this FOA.

**NIH programmatic priorities for this FOA are:**

- The role of innate and adaptive immune functions in the development and pathogenesis of asthma and allergic diseases with focus on severe asthma, chronic rhinosinusitis, atopic dermatitis and drug allergy;
- The impact of the microbiome and pollution on immune responses as they pertain to the development, prevention and management of asthma, allergic rhinitis, food allergy and atopic dermatitis;
• The interaction between infections and atopy and the role of immune responses to infections in the development and exacerbations of asthma, allergic rhinitis, chronic rhinosinusitis and atopic dermatitis;
• Induction of and understanding of the mechanisms of desensitization and sustained tolerance for the treatment and prevention of asthma, allergic rhinitis, food allergy and drug allergy;
• Genetic variations and epigenetic alterations affecting host immune responses to aeroallergens, food allergens and drug allergens;
• Clinical, immunologic and physiologic phenotyping and endotyping of drug allergy, atopic dermatitis, chronic rhinosinusitis and non-allergic rhinitis syndromes.

LIMIT ON NUMBER OF PROPOSALS PER ORGANIZATION
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

KEY DATES
If you are interested in this funding opportunity, please send a one-page summary of the proposed research and your biosketch to Eric Boberg (e-boberg@northwestern.edu) by November 1, 2016.

The sponsor application due date is April 3, 2017.

COLLABORATION OPPORTUNITIES
The Office of Research Development offers assistance in identifying and facilitating collaborations, putting together interdisciplinary teams, programmatic and administrative development of large, cross-school proposals, and leveraging institutional resources for outreach and education. Contact Nicole Moore (nicole.moore@northwestern.edu), Director, for more information.

CONTACT AND ADDITIONAL INFORMATION
Nicole Moore, Director, 847-467-0566, nicole.moore@northwestern.edu
Limited Submissions web site: ord.northwestern.edu/limited-submissions